Shanghai AI Drug-Discovery Firm Nutshell Therapeutics Closes Series C1 Round

Nutshell Therapeutics, also known in its home market as Yudao Bio, a Shanghai-based AI biotechnology and drug-discovery company, has closed a Series C1 funding round, raising tens of millions of US dollars from a group of investors including Trustbridge Capital, Decheng Capital, Dachen Caizhi and the Zhongsheng Xichuang Dingqi Fund. The company has not disclosed its total funding raised to date or a post-money valuation for the round.

The company operates within the fast-growing field of AI-driven drug discovery, applying machine learning models to accelerate the identification and optimisation of novel therapeutic compounds — a category that has attracted significant global investment as pharmaceutical companies and specialised biotech startups alike look to reduce the time and cost historically associated with traditional drug discovery processes, which can take well over a decade and cost billions of dollars per approved therapy.

China's AI-driven biotechnology sector has expanded rapidly over the past several years, supported by a combination of government industrial policy prioritising biotechnology innovation, a deep pool of computational biology and machine learning talent, and growing domestic capital availability for early and growth-stage life sciences companies. Shanghai in particular has emerged as one of China's leading hubs for AI-biotech convergence, hosting a dense cluster of research institutions, pharmaceutical companies and specialised venture capital firms focused on the sector.

The involvement of specialised healthcare and biotechnology-focused investors such as Trustbridge Capital and Decheng Capital in the round reflects the increasingly specialised nature of capital flowing into AI-drug-discovery companies, as investors with deep sector expertise seek to differentiate genuinely novel computational biology approaches from companies applying more generic AI tooling to pharmaceutical applications without meaningfully differentiated underlying science.

Globally, AI-driven drug discovery has become one of the more closely watched applications of artificial intelligence within life sciences, with proponents arguing the technology could meaningfully compress historically lengthy drug development timelines, while critics caution that the ultimate test of these platforms lies in their ability to produce clinically successful therapies — a bar that remains largely unproven at scale across the industry, despite substantial capital investment over the past several funding cycles.

With fresh capital from its Series C1 round, Nutshell Therapeutics is positioned to continue advancing its drug-discovery pipeline and computational platform, as competition within China's AI-biotech sector intensifies alongside continued government support for the broader life sciences innovation ecosystem.